BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Targeting the C1 Subtype of High Grade Serous Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms BEACON
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 22 Jan 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.